Search Results - "Aboo, Nazimuddin"

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease

    A Phase 2 Study of Tofacitinib, an Oral Janus Kinase Inhibitor, in Patients With Crohn’s Disease by Sandborn, William J, Ghosh, Subrata, Panes, Julian, Vranic, Ivana, Wang, Wenjin, Niezychowski, Wojciech

    Published in Clinical gastroenterology and hepatology (01-09-2014)
    “…Background & Aims Tofacitinib, an orally administered Janus kinase inhibitor, blocks signaling through γ-chain–containing cytokines (interleukins 2, 4, 7, 9,…”
    Get full text
    Journal Article
    Save to List
    Saved in:
  2. 2
    Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease

    Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease by Kelly, Ciarán P., Wilcox, Mark H., Glerup, Henning, Aboo, Nazimuddin, Ellison, Misoo C., Eves, Karen, Dorr, Mary Beth

    Published in Gastroenterology (New York, N.Y. 1943) (01-10-2018)
    Get full text
    Journal Article
    Save to List
    Saved in:
  3. 3
    Sa1765 - Characteristics and Outcomes in Patients with C. Difficile Infection (CDI) and Inflammatory Bowel Disease: Bezlotoxumab Versus Placebo

    Sa1765 - Characteristics and Outcomes in Patients with C. Difficile Infection (CDI) and Inflammatory Bowel Disease: Bezlotoxumab Versus Placebo by Kelly, Ciaran P., Wilcox, Mark, Glerup, Henning, Aboo, Nazimuddin, Eves, Karen, Dorr, Mary Beth

    Published in Gastroenterology (New York, N.Y. 1943) (01-04-2017)
    Get full text
    Journal Article
    Save to List
    Saved in:
  4. 4
    A phase II study of laquinimod in Crohn's disease

    A phase II study of laquinimod in Crohn's disease by D'Haens, Geert, Sandborn, William J, Colombel, Jean Frederic, Rutgeerts, Paul, Brown, Kurt, Barkay, Hadas, Sakov, Anat, Haviv, Asi, Feagan, Brian G

    Published in Gut (01-08-2015)
    “…Laquinimod is an oral therapeutic agent under investigation for the treatment of Crohn's disease (CD), Huntington's disease, lupus nephritis and multiple…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  5. 5
    Characteristics and Outcomes in Patients with C. Difficile Infection (CDI) and Inflammatory Bowel Disease: Bezlotoxumab Versus Placebo

    Characteristics and Outcomes in Patients with C. Difficile Infection (CDI) and Inflammatory Bowel Disease: Bezlotoxumab Versus Placebo by Kelly, Ciaran P, Wilcox, Mark, Glerup, Henning, Aboo, Nazimuddin, Eves, Karen, Dorr, Mary Beth

    Published in Gastroenterology (New York, N.Y. 1943) (01-04-2017)
    Get full text
    Journal Article
    Save to List
    Saved in:
  6. 6
    Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis

    Esomeprazole 40 mg administered intravenously has similar safety and efficacy profiles to the oral formulation in patients with erosive esophagitis by Schneider, Herbert, Van Rensburg, Christoffel, Schmidt, Stephen, Aboo, Nazimuddin, Makela, Heli, Nauclér, Emma, Hallerback, Bengt, Svedberg, Lars-Erik

    Published in Digestion (01-01-2004)
    “…An intravenous formulation of esomeprazole has been developed for use in patients where oral administration is not appropriate. This study evaluated safety…”
    Get more information
    Journal Article
    Save to List
    Saved in:
  7. 7
    HLA class I and II antigens in South African blacks with Graves' disease

    HLA class I and II antigens in South African blacks with Graves' disease by Omar, M A, Hammond, M G, Desai, R K, Motala, A A, Aboo, N, Seedat, M A

    Published in Clinical immunology and immunopathology (01-01-1990)
    “…A study was done to evaluate the relationship between Graves' disease and the HLA system in South African Blacks of Zulu descent. One hundred and three…”
    Get more information
    Journal Article
    Save to List
    Saved in:

Search Tools: